New data on the long-term efficacy and safety of dupilumab are very reassuring to patients with asthma, explained J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology.
New data on the long-term efficacy and safety of dupilumab are very reassuring to patients with asthma, explained J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology, a solo community-based practitioner at the Alabama Allergy & Asthma Clinic, and a clinical faculty member at the Alabama College of Osteopathic Medicine.
Transcript
What was the new data on dupilumab that was released at the European Respiratory Society meeting? What was the purpose of this open-label extension?
Well, the data that was presented the European Respiratory Society meeting on the long-term safety of diplomat was really pretty exciting. What it was it was an extension study of the previous studies that got dupilumab approved in the United States for asthma, and it was primarily, the primary end point was to demonstrate safety, but they also looked secondarily at the efficacy of dupilumab.
And did the results in the open-label extension study match what was found in the previous clinical trial findings or did anything change?
Well, now the study results are pretty cool. The rates of adverse events are similar to those that were observed in the initial intent-to-treat populations. And there were no new safety signals that were identified. And so it was very reassuring that the safety data that we saw in the very short-term studies that got this drug approved, now that we have these much longer-term studies, no new safety signals—the adverse events remain the same over the entire treatment course.
So, you know, it gives when I'm talking to patients about that, it's something very reassuring that we can talk to them about.
How do the findings that dupilumab is safe and effective in the long term add another weapon to the arsenal of providers who are treating patients with asthma?
Well, the long-term findings on dupilumab are really big to me. I may not be like all the doctors, but when I'm starting somebody on a biologic, I draw a laboratory evaluation…I'll look at the total eosinophil count. I'll report those to the patients. But then a month or so later, we come back in for a long visit—which I kind of call my shared decision-making visit—and then based on what their laboratory evaluation is, I tell them which biologics they would be eligible for based on FDA approval, or approval ratings on them. And then I say, “Well, you know, this is the advantage of this one, this is the disadvantage of this one.” And safety is a big thing. How long has it been around?
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Study Highlights BMP7 As a Potential Therapeutic Target for Ovarian Cancer
November 30th 2023High Bone Morphogenetic Protein 7 (BMP7) expression was significantly associated with aggressive phenotypes, including advanced grade, International Federation of Gynecology and Obstetrics stage, residual disease, and adverse overall survival.
Read More
What We’re Reading: ChatGPT in Health Care; Menthol Ban Meeting; Health System Cyberattack Impact
November 30th 2023ChatGPT is changing health care while also raising questions about artificial intelligence's promises and limitations; 24 Biden officials met with the National Organization of Black Law Enforcement Executives to discuss the FDA’s proposal to ban menthol cigarettes; a recent hospital cyberattack shows how the vulnerability of health care systems can put patients at risk.
Read More